Shipra Patel, MD, MS, is the senior medical director, global head of pediatrics, and global section head of endocrinology and metabolism at Parexel.

Structuring Obesity Trials to Optimize Patient Retention and Data Integrity

Despite not finding a “one-size-fits-all” approach, new research has shown that 

 trials largely depend on phase-appropriate operational design to ensure positive outcomes, including intensive oversight and scalable support strategies.

American Diabetes Association (ADA) Scientific Sessions 2026

 in New Orleans, Louisiana, by Shipra Patel, MD, MS, senior medical director, global head of pediatrics, and global section head of endocrinology and metabolism at Parexel, these data aim to provide clinicians with specific points to construct future trials around, prioritizing retention and the quality of endpoint data.

“We’ve looked really closely at ways that we could promote retention, and a lot of it comes down to making sure they know exactly what they’re getting into,” Patel told 

 in an exclusive interview. “For example, they need to know that they’ll probably experience mild to moderate gastrointestinal adverse events if they are on a GLP-1 or a related compound. It really helps to have patient education early on for those trials, and they’re more likely to stick it out through the trial.”

Prior research has been conducted on this topic, with high attrition cited as the inciting incident. Many weight loss agents currently in the pipeline can lead to gastrointestinal adverse events, and another study has noted that roughly 1 in 3 patients drop out of large-scale, phase 3 trials of these agents by 1 year. This naturally results in missing data, limiting the generalizability of a given study’s findings.

In an effort to counter this, Patel and colleagues conducted a review of 15 phase 1 and 2 obesity studies that took place between 2020 and 2025 in North America and Europe. These trials included first in human, dose escalation, and dose ranging studies, with structured post-study reviews and case study materials analyzed to find phase-specific best practices. The team emphasized site capabilities, patient experience, and retention in their search.

Based on these trials, the team noted that phase 1 studies typically benefit from intensive oversight from investigators, as well as in-house patient stays and early-phase units assessment expertise and body composition imaging. Additionally, standardized imaging workflows and structured patient training tended to support integrity of data and timely decision-making.

Phase 2 studies naturally required a focus on patient retention to ensure data integrity; to this end, Patel and colleagues found that participant compensation was the leading approach, despite not being consistently implemented. Transportation support and access to lifestyle counseling were also beneficial and were implemented in all 15 trials.

Patel also provided advice for clinicians or investigators currently constructing phase 1 or 2 obesity trials, suggesting main areas of focus to ensure both patient retention and quality data collection.

“I think in terms of the phase 1 trials, it’s important to look closely at the eligibility criteria to see if the representative patient population will be included, and to make sure that they are being handled in the right facility,” Patel said. “For phase 2 trials, the critically important thing is to have flexibility in the dosing schedule – if a patient is on a GLP-1 and they experience GI effects, you might have to back down on the dosing a bit, and then go back up again.”

Editors’ Note: Patel reports no relevant disclosures.

Patel S, Eniu I. Patient-Centered Strategies to Optimize Phase I and II Obesity Trials. Abstract presented at the American Diabetes Association (ADA) Scientific Sessions 2026, New Orleans, LA. June 5-8, 2026.

Delahanty LM, Riggs M, Klioze SS, Chew RD, England RD, Digenio A. Maximizing retention in long-term clinical trials of a weight loss agent: use of a dietitian support team. Obes Sci Pract. 2016;2(3):256-265. 

Videos

Shipra Patel, MD, MS, discusses her recent study highlighting best practices for phase 1 and 2 obesity trials to avoid attrition and loss of data.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

(PAH) has undergone a fundamental transformation over the past 4 decades, from a condition with median survival of approximately 2.8 years from diagnosis — established by the landmark 1984 NIH registry — to 1 managed with multi-pathway combination regimens capable of substantially improving hemodynamics and functional outcomes.¹ 

The approval of sotatercept (Winrevair; Merck) by the US Food and Drug Administration in March 2024 marked the introduction of the first activin signaling inhibitor in PAH, representing a mechanistically distinct fourth pathway beyond the prostacyclin, endothelin receptor antagonist, and nitric oxide/cyclic GMP axes that have defined therapy for decades. Pivotal data from the STELLAR trial, published in the 

 in 2023, demonstrated statistically significant improvements in 6-minute walk distance, functional class, and a composite of worsening events — including an 84% risk reduction versus placebo — in 323 patients on background dual or triple therapy.² The subsequent phase 3 ZENITH trial, also published in the 

 in 2025, evaluated sotatercept in WHO functional class III/IV patients on maximal background therapy and showed a 76% reduction in the composite of all-cause death, transplant, and PAH-related hospitalization; the trial was stopped early for efficacy.³ The HYPERION trial, published later in 2025, further demonstrated significant reductions in clinical worsening events in patients with PAH diagnosed within the first year, extending the evidence base to earlier disease.⁴

 convened a panel of pulmonologists and advanced lung disease specialists from Inova Fairfax Hospital and Howard University Hospital for an in-depth roundtable discussion on overcoming barriers to optimal PAH care. The forum was moderated by Vik Khangoora, MD, a pulmonologist and critical care physician at Inova Fairfax, and included advanced lung disease specialists alongside general pulmonologists and critical care clinicians from both institutions. The composition of the panel — spanning a referral center of excellence, community-connected pulmonology, and inpatient critical care — allowed for a wide-ranging discussion bridging clinical trial data with the administrative and logistical realities of prescribing PAH therapy in an insurance-constrained environment. The discussion was structured around 4 primary domains: initial therapy selection and risk stratification, prostacyclin escalation and de-escalation in the sotatercept era, monitoring and composite endpoints, and systemic barriers to optimal care.

"I tend to like to be aggressive up front and rather step down then have to step up... get them on parenteral prostacyclin, reassess risk, get them on maybe convert to the Orenitram or Uptravi other than being stuck on the parenteral prostacyclin,” one panelist said.

The forum reached broad consensus that sotatercept has meaningfully shifted prescribing behavior for escalation therapy. Most panelists indicated they now reach for Winrevair ahead of inhaled or oral prostacyclins in intermediate-high-risk patients on dual therapy, driven primarily by STELLAR and ZENITH efficacy data and the practical appeal of a bimonthly subcutaneous injection over four-times-daily inhaled treprostinil.²,³ Several panelists described an aggressive upfront approach in high-risk patients — initiating parenteral prostacyclins followed by sotatercept addition — with an explicit goal of subsequent de-escalation once hemodynamics improve, a strategy that remains without prospective validation. Risk stratification was described as a multimodal, every-visit exercise, with most panelists relying on whichever validated tool — REVEAL 2.0, REVEAL Lite, COMPERA, or the ESC/ERS 3- or 4-Strata model — showed the worse risk, and maintaining a low threshold for repeat right heart catheterization when clinical and objective data were discordant. Khangoora raised real-world safety signals not yet reflected in trial publications — specifically pericardial effusions and non-reversing pulmonary shunting associated with sotatercept in routine practice — and the panel debated whether the availability of Winrevair is inadvertently delaying transplant evaluation in patients who should be referred sooner, an unintended consequence no trial has yet examined.

Insurance coverage was identified as the most significant systemic barrier to optimal PAH care, with prior authorization denials for sotatercept and inhaled treprostinil (Yutrepia) described as increasingly common; peer-to-peer physician review was cited as the most reliable mechanism for overturning them. Medication adherence was flagged as a greater challenge than clinical intuition might suggest: a meta-analysis of 14 studies encompassing more than 14,000 patients found approximately 60.9% (95% CI, 52.3%–69.1%) of patients with PAH met adherence criteria, with a discontinuation rate of 42.3%.⁵ Non-persistence carries measurable consequences — a retrospective cohort study found nonadherence to PDE5 inhibitors was associated with more than double the risk of mortality (hazard ratio [HR], 2.33; 95% CI, 1.79–3.03; 

 <.001), with an even greater risk for ERA nonadherence (HR, 5.43; 95% CI, 3.33–8.85; 

 <.001).⁶ The panel proposed pharmacist-led check-in models and industry nursing support programs as underutilized mechanisms for improving persistence. A well-documented diagnostic delay adds further urgency to these concerns: nationwide US data have shown a median time from symptom onset to PAH diagnosis exceeding 2 years, with symptoms frequently attributed to asthma or deconditioning in primary care settings.⁷ Evidence gaps highlighted for future research included de-escalation outcomes after prostacyclin-to-oral therapy transition, endothelin receptor antagonist use in mixed-group PAH with concurrent interstitial lung disease or sarcoidosis, dose equivalency formulas for same-class prostacyclin switches, and the role of four-strata versus three-strata risk assessment at treatment initiation.

D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. 

 1991;115(5):343–349. doi:10.7326/0003-4819-115-5-343

Hoeper MM, Badesch DB, Ghofrani HA, et al; STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. 

 2023;388(16):1478–1490. doi:10.1056/NEJMoa2213558

Humbert M, McLaughlin VV, Badesch DB, et al; ZENITH Trial Investigators. Sotatercept in patients with pulmonary arterial hypertension at high risk for death. 

 2025;392(20):1987–2000. doi:10.1056/NEJMoa2415160

McLaughlin VV, Hoeper MM, Badesch DB, et al; HYPERION Trial Investigators. Sotatercept for pulmonary arterial hypertension within the first year after diagnosis. 

 2025;393(16):1599–1611. doi:10.1056/NEJMoa2508170

Raina A, DeTurk WE, Walpole SC, et al. Real-world adherence and persistence of upfront therapy in patients with pulmonary arterial hypertension in the United States. 

[Author TK]. PAH medication nonadherence linked to worse outcomes, higher mortality. 

 2026 [full citation pending final PubMed indexing; findings reported by Pulmonology Advisor, February 2026; Komodo Research Database claims cohort, 2017–2022].

Nair A, Sherif M, Bhagat A, Duggal A. Time to diagnosis of pulmonary hypertension and diagnostic burden: a retrospective analysis of nationwide US healthcare data. 

 Published online January 6, 2023. doi:10.1002/pul2.12188

Articles

Sotatercept has introduced a fourth, mechanistically distinct PAH treatment pathway and is reshaping escalation strategies after robust phase 3 outcomes across advanced and earlier-diagnosed disease. In clinical practice, many clinicians now prioritize sotatercept before inhaled/oral prostacyclins for intermediate-high risk patients on dual therapy, while using parenteral prostacyclin up front in high-risk patients with an intent to later de-escalate. Risk assessment is iterative and multimodal, but real-world safety signals, transplant-timing concerns, insurance friction, and suboptimal adherence remain major constraints.

An expert clinical forum explores recent updates in the field and incorporating sotatercept treatment.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Sotatercept, De-escalation, and Systemic Barriers: A PAH Expert Forum

Aleena Banerji, MD, professor at Harvard Medical School and director of clinical care at the Center for Drug and Vaccine Allergy at Massachusetts General Hospital.

HAELO Phase 3: Lonvo-z Secondary Endpoints, QoL Data Detailed at EAACI

Lonvoguran ziclumeran (lonvo-z; Intellia Therapeutics), a one-time in vivo CRISPR gene-editing therapy for

, continued to demonstrate compelling efficacy across secondary endpoints in the phase 3 HAELO trial. The team presented new HAELO data in a late-breaking oral session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026 in Istanbul and simultaneously published it in the 

 following the meeting, lead investigator Aleena Banerji, MD, professor at Harvard Medical School and director of clinical care at the Center for Drug and Vaccine Allergy at Massachusetts General Hospital, said the secondary endpoint data exceeded her expectations despite entering phase 3 with cautious optimism.

“Going into any phase 3 study [is] unpredictable [in terms of] what the efficacy is going to be,” Banerji said. “It was very exciting to see that not only did the data match what was being seen in the prior phase 1 and phase 2 study, but it really exceeded expectations."

Secondary Endpoints and HAE Attack Reductions

As previously reported, HAELO met its primary endpoint with an 87% reduction in mean monthly attacks in the lonvo-z arm versus placebo during the efficacy evaluation period from weeks 5 to 28.

 The newly disclosed secondary data built further on that result.

The monthly rate of moderate and severe attacks was reduced by 91% in patients receiving lonvo-z compared with placebo (0.11 vs. 1.23; 

 <.0001), and the monthly rate of attacks requiring on-demand treatment fell by 89% (0.19 vs. 1.79; 

Banerji called the absence of non-responders a particularly meaningful finding. Patient-level data demonstrated that all patients in the lonvo-z arm experienced attack-rate reductions from baseline during weeks 5 to 28.

"It's rare that we see that when you look across a lot of other trials or even outside of hereditary angioedema," Banerji said.

Quality of Life Improvements With Lonvo-Z

Patients receiving lonvo-z experienced a mean improvement of 17.04 points in the Angioedema Quality of Life (AE-QoL) total score compared with approximately 6.5 points in the placebo arm, a difference that exceeded the 6-point threshold considered clinically meaningful.

Banerji said that threshold context matters when interpreting the magnitude of that gain. “A 17-point change far exceeds what we believe is clinically meaningful," she noted. Patients in the trial reported being able to think differently about work, school, and travel—including activities like taking a cruise—without organizing their lives around the fear of an impending attack.

"It's the constant fear of that next attack and when it's going to occur," Banerji said. "Being able to change that and seeing this significant improvement in quality-of-life matching what we're seeing with efficacy is really promising for the real world."

The HAELO population included patients across a range of prior treatment histories, from those naive to long-term prophylaxis (LTP) to those who were attack-free on existing regimens. Notably, 20% of enrolled patients reported having complete disease control as their best response to prior long-term prophylaxis therapies and yet still chose to enroll.

Banerji addressed why patients already well-controlled on LTP would pursue an investigational gene editing therapy: the burden of treatment itself, including insurance approvals, supply management, and injection schedules.

“Just because they're doing well on long-term prophylaxis in terms of not having attacks or feeling that they are attack-free isn't the only aspect of hereditary angioedema,” she said.

All treatment-emergent adverse events (TEAEs) reported in the lonvo-z arm were mild or moderate, with no serious adverse events observed. The most common TEAEs exceeding placebo rates were infusion-related reactions, headache, fatigue, back pain, and upper respiratory tract infection.

Banerji said the safety monitoring focus centered on liver function, given the hepatic targeting mechanism of an in vivo CRISPR therapy. No transient or persistent elevations in liver function tests were observed, and infusion reactions resolved without interrupting dosing in any patient.

Plasma kallikrein levels decreased substantially by the first measurement at day 15, reached a steady state by week 5, and remained stable through the data cutoff of February 10, 2026, with all patients remaining LTP-free as of that date. 

Banerji said durability questions will require continued follow-up but drew confidence from the longer-term phase 1 and phase 2 data.

A rolling BLA submission for lonvo-z was initiated in April, and the company continues to anticipate regulatory approval and a US launch in the first half of 2027.

 When asked which patients she would prioritize, Banerji said her view has shifted toward broad candidacy.

"I think that every patient is eligible," she said. "The concerns are going to be around insurance and navigating some of those challenges, but in terms of talking to patients… we are going to help them understand that this is a newer treatment that's coming up on the market...and then go through all of the data, the efficacy, the safety concerns, the potential benefit, [and] risks. [We] help them think through this in a shared decision-making process so that they themselves can be the person that decides [if] is this the right treatment for them.”

Editor’s note: Reported disclosures for Banerji include CSL Behring and BioCryst Pharmaceuticals.

Intellia Therapeutics. Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema. June 13, 2026. 

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-additional-positive-phase-3

Derman C. Single-Dose Lonvo-z Cuts HAE Attacks by 87% in Phase 3 Trial, With Aleena Banerji, MD. HCPLive. Published May 11, 2026. 

https://www.hcplive.com/view/single-dose-lonvo-z-cuts-hae-attacks-87-phase-3-trial-aleena-banerji-md

Aleena Banerji, MD, reviews HAELO secondary data: 91% reduction in moderate/severe attacks, 17-point QoL gain, and zero non-responders for lonvo-z.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Bharat Saboo, MS, is the director of Prayas Diabetes Center.

Mitraa-T1D: AI-Driven Converastional Tool Improves T1D Diabetes Distress, Self-Care Behaviors

The usage of a digital conversational support tool resulted in improved glycemic control and self-care behaviors, as well as reduced diabetes distress, in adults with 

American Diabetes Association (ADA) Scientific Session 2026 

in New Orleans, Louisiana, by Bharat Saboo, MS, director of Prayas Diabetes Center in Indore, India, this study, titled Mitraa-T1D, evaluates the effectiveness of the Mitraa tool in managing a patient’s mental and emotional stress following diagnosis of and during treatment for T1D.

“We have a patchy healthcare system in our country, and it is not possible for us at any point in time to provide 24/7 continuous care and coverage to our patients,” Saboo told 

 in an exclusive interview. “We wanted to see if this device could improve patients’ distress scores, which is a very common problem with type 1 diabetes patients.”

Diabetes distress, unlike standard depressive symptoms, is directly linked to poor glycemic control and problematic self-care behaviors. Patients with either T1D or 

 are susceptible to elevated diabetes distress, and research has shown that it affects roughly 40 to 50% of adults and ≤60% of adolescents with T1D. Given these statistics, clinicians have concluded that diabetes distress represents a significant clinical problem.

To this end, Saboo and colleagues implemented Mitraa-T1D, an AI-driven digital support platform, among patients in India with T1D. A total of 308 adult patients with T1D – defined as HbA1c ≥7% - were enrolled to this 6-month, multicenter, parallel-group randomized controlled trial. These patients were randomly assigned in a 1:1 ratio to receive either usual care plus digital conversational support or usual care alone. Pregnant patients, as well as those with recent diabetic ketoacidosis, severe hypoglycemia, severe cognitive impairment, or advanced renal disease were excluded.

Saboo and colleagues assessed patients’ self-care behaviors via the Summary of Diabetes Self-Care Activities (SDSCA), and diabetes distress was monitored via the Diabetes Distress Scale. The study’s primary endpoint was change in HbA1c, while secondary outcomes included self-monitoring of blood glucose and physical activity.

HbA1c data were available for 292 of the 308 enrolled patients (94.8%), and mean age among these patients was 30.2 +/- 9.6 years. By the end of the study, mean HbA1c had decreased from 8.2 +/- 1% to 7.5 +/- 0.9% in the intervention group compared with 8.1 +/- 1.1% to 7.9 +/- 1% in the usual care group. This yielded a between-group difference of -0.5% (

 <.001). SDSCA scores also improved more in the intervention group (+1.3 vs +0.4; 

 <.001), and Diabetes Distress Scale scores declined by -0.8 in the intervention group compared to -0.3 in the usual care group (

 <.001). Mean self-monitoring of blood glucose frequency increased from 4 to 7 checks per day versus 4 to 5.

Saboo and colleagues concluded that the use of Mitraa was associated with these improvements in both physical and psychological symptoms of T1D.

Saboo also discussed the developmental process behind the device, pointing out that Mitraa was not a fully autonomous AI but instead a Large Language Model (LLM). The device is not designed to prescribe treatments or medications to patients – instead, Saboo emphasizes that it is simply programmed to serve as a conversational tool for patients unable to contact or visit their endocrinologists.

“The biggest advantage with Mitraa is that we have sandboxed it – it doesn’t give any treatment, it just acts as a buddy,” Saboo said. “It doesn’t prescribe insulin, it never adjusts the dose of insulin, it just directs the patient to connect with the doctor.”

Editors’ Note: Saboo reports no relevant disclosures.

Saboo B, Saboo S, Modi A, et al. Mitraa-T1D: A Multicenter Randomized Trial of a Digital Conversational Support Tool in Adults with Type 1 Diabetes. Abstract presented at the American Diabetes Association (ADA) Scientific Sessions 2026, New Orleans, LA. June 5-8, 2026.

Fisher L, Hessler D, Polonsky W, Strycker L, Masharani U, Peters A. Diabetes distress in adults with type 1 diabetes: Prevalence, incidence and change over time. J Diabetes Complications. 2016;30(6):1123-1128. 

Bharat Saboo, MS, discusses his recent study investigating the LLM device in improving both physical and psychological issues associated with T1D.

Type 1 Diabetes

Samuel Shangwu Wu, PhD, is a professor and deputy director of the Health Informatics Institute at the University of South Florida.

Time to Minimum Residual C-Peptide As a Predictor of Treatment Efficacy in T1D

Time to minimum residual C-peptide (TMRCP) is a clinically interpretable and statistically efficient endpoint for future studies in 

 in New Orleans, Louisiana, by Samuel Shangwu Wu, PhD, professor and deputy director of the Health Informatics Institute at the University of South Florida, these data reflect a potentially more reliable endpoint for patients with T1D enrolled in clinical trials, utilizing all available longitudinal data to provide a stable and reliable efficacy measure.

Existing methods of measuring beta-cell function have historically proven difficult due to the challenges inherent in direct tissue sampling. Alternative methods, including insulin or C-peptide measurements, are similarly difficult due to changing levels of insulin resistance or cellular exhaustion.

“We feel that this time is more interpretable, and the patients will be easier to understand,” Wu told 

 in an exclusive interview. “And then we estimated that time with, of course, some extrapolation, and then we used these to compare whether their treatment is effective or not beyond the single time point in the measurement.”

TMRCP is defined as the time until C-peptide drops to a prespecified value, which represents the functional loss of beta-cell secretory capacity. Wu and colleagues estimated TMRCP by utilizing a nonlinear mixed-effects model and applying it to log-transformed mean area under curve (MAUC) C-peptide values collected via mixed-meal tolerance testing. The team states that this approach utilizes all available longitudinal measurements while accounting for repeated observations within individuals. Additionally, the strategy can manage variable visit schedules or incomplete follow-up from a given patient.

Wu and colleagues applied this estimation framework to 6 randomized, placebo-controlled, double-blind trials, the results of which were collected via TrialNet. Each trial investigated patients with recent-onset T1D, totaling 597 participants. Via Wilcoxon rank-sum tests on TMRCP estimates, the team highlighted the same 3 main treatments as effective as the original analyses.

Median TMRCP for the 3 effective treatments compared to placebo were 128 vs 84 days for Rituximab (

 = .03), and 110 vs 53 days for anti-thymocyte globulin (

 = .027). Differences were <4 days for the 3 non-effective treatments, including canakinumab, mycophenolate mofetil and daclizumab combined therapy, and glutamic acid decarboxylase.

Ultimately, the team concluded that, unlike fixed-time endpoints, TMRCP measures the loss of residual insulin secretion while providing patient-specific estimates to support robust treatment comparisons.

“For this TMRCP in the estimate, we used something like a random effect – in theory, we borrow the information from other patients to estimate each patient’s decline,” Wu said. “There is lots of variation between patients in terms of the rate of decline, but we borrow that information to estimate their slope and make it a little less variable.”

Editors’ Note: Wu reports disclosures with Vertex Pharmaceuticals and United HealthCare Services.

Wu S, Ding A, Krischer J, et al. Time to Minimal Residual C-Peptide as an Efficacy Measure in Recent-Onset Type 1 Diabetes Immunotherapy Trials. Abstract presented at the American Diabetes Association (ADA) Scientific Sessions 2026, New Orleans, LA. June 5-8, 2026.

Hannon TS, Kahn SE, Utzschneider KM, et al. Review of methods for measuring β-cell function: Design considerations from the Restoring Insulin Secretion (RISE) Consortium. 

Samuel Shangwu Wu, PhD, discusses his recent work evaluating TMRCP as an effective endpoint for future T1D trials.

DiRuggiero on PsO-LD, a heating pad for molluscum, and why psoriasis counseling must now include pulmonary risk.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Psoriasis-Associated Lung Disease and Clinical Pearls for Dermatologist 

Harrison Nguyen, MD, MBA, MPH, is a double board-certified dermatologist/Mohs micrographic surgeon and clinical researcher in Houston, Texas.

This video feature highlights the views of dermatologists on prior authorization, step therapy, and issues related to these processes.

The Cost of Delay: How Prior Authorization Is Impacting Dermatology

Dermatologists write up to 10% of US antibiotics. At SDPA 2026, Douglas DiRuggiero, PA-C, explains why that must change and what to use instead.

Antibiotic Stewardship in Dermatology: A Call to Prescribe Less

Explore APAPP’s Las Vegas meeting with hands-on POCUS and airway labs, COPD and ILD bootcamps, AI updates, and new therapy insights.

What to Expect at the 2026 APAPP National Conference

Brian E. Lacy, PhD, MD, a board-certified gastroenterologist at the Mayo Clinic in Jacksonville.

Brian Lacy, MD, PhD, of Mayo Clinic discussed the stepwise approach to diagnosing non-IgE mediated food hypersensitivity at EAC 2026.

Food Allergy

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Strategic Alliance Partnership

When Abdominal Pain Is Actually a Food Allergy: A GI Workup

Aboul-Fettouh walks through the clinical and patient-centered factors that move a patient from localized, monitored disease to systemic JAK-inhibitor therapy, emphasizing that SALT score thresholds from clinical trials do not define the real-world trigger for treatment escalation.


Video Series

Identifying Patients for Systemic Therapy: Beyond

Elizabeth A. Kiracofe, MD, is a board-certified dermatologist and the founder of Airia Comprehensive Dermatology, located in downtown Chicago's Fulton Market District, where she practices medical, surgical, and cosmetic dermatology.

Podcasts

This discussion centers on patient empowerment, shared decision-making, and advancing equitable dermatologic care for those with skin of color.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Skin of Color Savvy: Patient Power—Voices Driving Change in Skin of Color Care

Aboul-Fettouh addresses a persistent misconception among referring clinicians-that AA hair loss will resolve spontaneously-and makes the case for earlier referral and treatment initiation to preserve the greatest opportunity for hair regrowth.


What Referring Physicians Should Know: Avoiding the "Wait and See" Approach

Experts explore why FCS remains one of the most emotionally and clinically challenging lipid disorders despite decades of management effort.

Clinical Burden and Unmet Need in Familial Chylomicronemia Syndrome

Oksana Hamidi, DO, is an associate professor in the division of endocrinology and metabolism at UT Southwestern Medical Center

Two-year CAHtalyst data show crinecerfont sustained glucocorticoid reduction and improved metabolic outcomes in classic CAH.


Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Latest News

Structuring Obesity Trials to Optimize Patient Retention and Data Integrity

Sotatercept, De-escalation, and Systemic Barriers: A PAH Expert Forum

HAELO Phase 3: Lonvo-z Secondary Endpoints, QoL Data Detailed at EAACI

Mitraa-T1D: AI-Driven Converastional Tool Improves T1D Diabetes Distress, Self-Care Behaviors

Time to Minimum Residual C-Peptide As a Predictor of Treatment Efficacy in T1D